Regeneron Pharmaceuticals
Stock Forecast, Prediction & Price Target
Regeneron Pharmaceuticals Financial Estimates
Regeneron Pharmaceuticals Revenue Estimates
Regeneron Pharmaceuticals EBITDA Estimates
Regeneron Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $16.07B N/A | $12.17B -24.25% | $13.11B 7.75% | Avg: $14.92B Low: $14.92B High: $14.92B avg. 13.75% | Avg: $16.00B Low: $16.00B High: $16.00B avg. 7.24% | Avg: $17.24B Low: $17.24B High: $17.24B avg. 7.77% | Avg: $18.33B Low: $18.33B High: $18.33B avg. 6.33% |
Net Income
% change YoY
| $8.07B N/A | $4.33B -46.27% | $3.95B -8.86% | Avg: $5.39B Low: $5.39B High: $5.39B avg. 36.35% | Avg: $5.99B Low: $5.99B High: $5.99B avg. 11.17% | Avg: $6.68B Low: $6.68B High: $6.68B avg. 11.51% | Avg: $7.28B Low: $7.28B High: $7.28B avg. 8.96% |
EBITDA
% change YoY
| $9.38B N/A | $5.17B -44.86% | $4.69B -9.27% | Avg: $6.37B Low: $6.37B High: $6.37B avg. 35.82% | Avg: $6.83B Low: $6.83B High: $6.83B avg. 7.24% | Avg: $7.36B Low: $7.36B High: $7.36B avg. 7.77% | Avg: $7.83B Low: $7.83B High: $7.83B avg. 6.33% |
EPS
% change YoY
| $76.4 N/A | $40.51 -46.97% | $37.05 -8.54% | Avg: $47.41 Low: $47.41 High: $47.41 avg. 27.97% | Avg: $52.71 Low: $52.71 High: $52.71 avg. 11.17% | Avg: $58.78 Low: $58.78 High: $58.78 avg. 11.51% | Avg: $64.05 Low: $64.05 High: $64.05 avg. 8.96% |
Operating Expenses
% change YoY
| $4.68B N/A | $5.61B 19.86% | $7.25B 29.11% | Avg: $2.62B Low: $2.62B High: $2.62B avg. -63.80% | Avg: $2.81B Low: $2.81B High: $2.81B avg. 7.24% | Avg: $3.03B Low: $3.03B High: $3.03B avg. 7.77% | Avg: $3.22B Low: $3.22B High: $3.22B avg. 6.33% |
FAQ
What is Regeneron Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 17.00% in 2025-2028.
We have gathered data from N/A analysts. Their low estimate is 5.39B, average is 5.39B and high is 5.39B.
What is Regeneron Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 8.77% in 2025-2028.
We have gathered data from N/A analysts. Their low revenue estimate is $14.92B, average is $14.92B and high is $14.92B.
What is Regeneron Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 14.90% in 2025-2028.
We have gathered data from N/A analysts. Their low earnings per share estimate is $47.41, average is $47.41 and high is $47.41.